Core Xarelto Patent Expiration
Xarelto (rivaroxaban), made by Bayer and Janssen, has its primary U.S. composition-of-matter patent (U.S. Patent No. 7,157,456) expiring on September 30, 2024. This covers the drug's active ingredient and marks the key date for generic entry potential.[1][2]
When Will Generics Hit the Market?
Generics may launch as early as October 1, 2024, but a 180-day FDA exclusivity period for first generic filers (awarded to entities like Mylan and Sandoz) delays others until around March 2025. Bayer has settled with multiple ANDA filers, allowing some launches starting January 1, 2028, or earlier via authorized generics.[1][3]
Remaining Patents and Exclusivity Barriers
Xarelto faces 20+ additional U.S. patents listed in the FDA Orange Book, covering formulations, uses (e.g., DVT/PE treatment), and processes. The latest expires May 31, 2032 (e.g., U.S. Patent No. 9,326,945 for combination therapy). Pediatric exclusivity adds six months to some, pushing to 2033. Challenges via Paragraph IV litigation continue, with courts upholding most Bayer patents.[1][2][4]
International Patent Timelines
- Europe: Core patent expired 2018; generics available since.
- Japan: Expires 2025.
- Canada: Core expired 2020.[1][2]
Impact on Pricing and Availability
Post-2024 expiry of the main patent, U.S. prices could drop 70-90% with generic competition, based on similar anticoagulants like Eliquis. Patients on Xarelto should check insurance formulary changes around Q4 2024.[3][5]
Check Latest Patent Status
Patent landscapes shift with litigation. For real-time U.S. Orange Book data and global expiries, visit DrugPatentWatch.com.[1]
Sources
[1]: DrugPatentWatch.com - Xarelto Patents
[2]: FDA Orange Book - Xarelto
[3]: FDA Generic Approvals - Rivaroxaban
[4]: USPTO Patent Database
[5]: IQVIA Market Data on Anticoagulants